1. FDA. In: CDER Fast Track Products Approved Since 1998 through June 1, 2010. 2010. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM216527.pdf . Accessed 15 Dec 2010.
2. ANVISA. Agência Nacional de Vigilância Sanitária. In: Resolução—RE 1229 de 14 de agosto de 2001. 2001. http://www.anvisa.gov.br . Accessed 15 Dec 2010.
3. Ribeiro JAA, Campos LMM, Alves RJ, Lages GP, Pianetti GA. Efavirenz related compounds preparation by hydrolysis procedure: setting reference standards for chromatographic purity analysis. J Pharm Biomed. 2007;43:03–298.
4. Sathigari S, Chadha G, Lee YP, Wright N, Parsons DL, Rangari VK, Fasina O, Babu RJ. Physicochemical characterization of efavirenz—cyclodextrin inclusion complexes. AAPS Pharm Sci Technol. 2009;10(1):81–7.
5. Chiappetta DA, Lorenzo CA, Rico AR, Taboada P, Concheiro A, Sosnik A. N-alkylation of poloxamines modulates micellar encapsulation and release of the antiretroviral efavirenz. Eur J Pharm Biopharm. 2010;76:24–37.